UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): April 26, 2011

PolyMedix, Inc.

(Exact Name of Issuer as Specified in Charter)

 

 

 

 

 

 

Delaware

  

000-51895

  

27-0125925

(State or Other Jurisdiction of

Incorporation or Organization)

  

(Commission File Number)

  

(I.R.S. Employer

Identification Number)

 

 

 

 

170 N. Radnor-Chester Road; Suite 300

Radnor, Pennsylvania

  

19087

(Address of Principal Executive Offices)

  

(Zip Code)

(484) 598-2400

(Registrant’s Telephone Number, Including Area Code)

 

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

¨

Written communications pursuant to Rule 425 under the Securities Act

 

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act

 

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

 

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 


 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 26, 2011, Frank Slattery, Jr. (73) informed the board of directors of PolyMedix, Inc. (the “Company”) that, for personal reasons and not any disagreement with the Company, he would not stand for re-election to the board of directors of the Company at the Company’s 2011 annual meeting of stockholders to be held on June 17, 2011.    Mr. Slattery currently serves as the Chairman of the board of directors and as a member of the Audit Committee and the Nominating and Corporate Governance Committee.  Shaun O’Malley is expected to serve as Chairman of the board of directors upon Mr. Slattery’s completion of his present term as director of the Company.

 

 


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

  

PolyMedix, Inc.

 

 

 

Date: April 29, 2011

 

By:

 

/s/ Edward F. Smith

 

  

 

  

 

 

  

 

  

Edward F. Smith

Vice President, Finance and Chief Financial Officer